Compare BIOA & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIOA | NAVI |
|---|---|---|
| Founded | 2015 | 1973 |
| Country | United States | United States |
| Employees | 62 | 670 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.6M | 771.2M |
| IPO Year | N/A | N/A |
| Metric | BIOA | NAVI |
|---|---|---|
| Price | $17.79 | $8.31 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 7 |
| Target Price | ★ $51.50 | $11.57 |
| AVG Volume (30 Days) | 472.7K | ★ 814.4K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 7.42% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $846.41 | $75.26 |
| Revenue Next Year | N/A | $15.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.38 | $7.86 |
| 52 Week High | $24.00 | $16.07 |
| Indicator | BIOA | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 43.97 |
| Support Level | $15.47 | $7.86 |
| Resistance Level | $22.17 | $8.40 |
| Average True Range (ATR) | 1.30 | 0.24 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 41.86 | 42.68 |
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.